In a phase IIb study, Tavo (tavokinogene telseplasmid) in combination with Keytruda (pembrolizumab) led to a 30% overall response rate in the first 54 out of 100 planned patients who have rigorously defined anti-PD1 checkpoint resistant metastatic melanoma.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe